Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AlloVir (ALVR)
NASDAQ:ALVR
AlloVir (ALVR) Stock Price & Analysis
341 Followers
ALVR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $6.12
Previous Close$0.78
Volume184.37K
Average Volume (3M)475.33K
Market Cap
$87.65M
Enterprise Value-$68.86M
Total Cash (Recent Filing)$183.94M
Total Debt (Recent Filing)$27.43M
Price to Earnings (P/E)-0.5
Beta1.29
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding115,003,325
10 Day Avg. Volume407,315
30 Day Avg. Volume475,335
Standard Deviation0.24
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.61
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.36
Forecast
1Y Price Target
$1.00Price Target Upside28.97% Upside
Rating ConsensusHold
Number of Analyst Covering1
AlloVir News
PremiumCompany Announcements
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
Bulls Say, Bears Say
Bulls Say
Cost ManagementALVR demonstrates effective cost management as evidenced by SG&A expenses coming in below analyst and consensus estimates.
Financial StabilityALVR boasts a strong cash reserve, ensuring operational funding for an extended period.
Investment In GrowthALVR's higher than anticipated R&D spending signals a commitment to future growth and innovation.
Bears Say
Corporate StrategyALVR has not set a timetable for the completion of its strategic review, leaving investors uncertain about the company's future direction.
Cost ManagementALVR's SG&A expenses exceeded both analyst and consensus estimates, raising concerns about the company's cost control measures.
Financial PerformanceR&D expenses for ALVR were significantly higher than analyst and consensus estimates, potentially impacting profit margins.
---
Ownership Overview
Currently, No data available
---
ALVR FAQ
What was AlloVir’s price range in the past 12 months?
AlloVir lowest stock price was $0.58 and its highest was $6.12 in the past 12 months.
What is AlloVir’s market cap?
Currently, no data Available
When is AlloVir’s upcoming earnings report date?
AlloVir’s upcoming earnings report date is Aug 01, 2024 which is in 73 days.
How were AlloVir’s earnings last quarter?
AlloVir released its earnings results on May 02, 2024. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of -$0.237 by -$0.027.
Is AlloVir overvalued?
According to Wall Street analysts AlloVir’s price is currently Undervalued.
Does AlloVir pay dividends?
AlloVir does not currently pay dividends.
What is AlloVir’s EPS estimate?
AlloVir’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlloVir have?
AlloVir has 115,003,330 shares outstanding.
What happened to AlloVir’s price movement after its last earnings report?
AlloVir reported an EPS of -$0.264 in its last earnings report, missing expectations of -$0.237. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AlloVir?
Among the largest hedge funds holding AlloVir’s share is Woodline Partners LP. It holds AlloVir’s shares valued at 2M.
---
AlloVir Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (28.97% Upside)
$1.00 (28.97% Upside)
Blogger Sentiment
Bullish
ALVR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $37.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.32%
12-Months-Change
Fundamentals
Return on Equity
-114.36%
Trailing 12-Months
Asset Growth
-40.94%
Trailing 12-Months
Company Description
AlloVir
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
---
ALVR Stock 12 Month Forecast
Average Price Target
$1.00
▲(28.97% Upside)
Technical Analysis
Best Analysts Covering ALVR
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-51.41%
downgraded a sell rating 5 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -51.41% per trade.
---